SIOXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 2月 2024 @ 05:58):

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases...

Stats
本日の出来高	7 588.00
平均出来高	62 408.00
時価総額	35.36M
EPS	$0 ( 2024-02-09 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.226
ATR14	$0.0220 (4.60%)

Insider Trading

Date	Person	Action	Amount	type
2022-02-08	Meswani Parag V	Buy	153 700	Restricted Stock Units
2022-02-08	Nassif David W.	Buy	546 500	Restricted Stock Units
2022-01-28	Meswani Parag V	Sell	0	Common Stock
2022-01-28	Meswani Parag V	Sell	15 625	Stock Option (Right to Buy)
2022-01-28	Meswani Parag V	Sell	12 500	Stock Option (Right to Buy)

INSIDER POWER
0.00
Last 89 transactions
Buy: 137 127 498 \| Sell: 478 048

ボリューム相関

長: 0.43 (neutral)

短: 0.16 (neutral)

Signal:(83.213) Neutral

Sio Gene Therapies Inc. 相関

10 最も正の相関
TACO	0.952
GGAL	0.949
NWLI	0.946
AMYT	0.938
ACIW	0.938
RXDX	0.937
BKCH	0.931
NYMTP	0.93
WLFC	0.929
HWCC	0.928

10 最も負の相関
LARK	-0.941
PCRX	-0.94
GOSS	-0.936
SMMF	-0.935
MARK	-0.928
HMNF	-0.924
THTX	-0.919
USCB	-0.919
RIVN	-0.917
XFOR	-0.915

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Sio Gene Therapies Inc. 相関 - 通貨/商品

0.27
( neutral )

0.48
( neutral )

0.00
( neutral )

0.29
( neutral )

0.00
( neutral )

-0.18
( neutral )

Sio Gene Therapies Inc. 財務諸表

Annual	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2022
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$-0.980

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.620

Financial Reports:

No articles found.

Sio Gene Therapies Inc.

Sio Gene Therapies Inc., a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. It has a license agreement with Oxford BioMedica (UK) Ltd. to develop and commercialize AXO-Lenti-PD and related gene therapy products; and The University of Massachusetts Medical School to develop and commercialize gene therapy product candidates, including AXO-AAV-GM1 and AXO-AAV-GM. The company was formerly known as Axovant Gene Therapies Ltd. and changed its name to Sio Gene Therapies, Inc. in November 2020. Sio Gene Therapies, Inc. was incorporated in 2014 and is based in New York, New York.